产品中心
当前位置：首页>产品中心Anti-Apolipoprotein A V/Cy7
货号： bs-5035R-Cy7 基本售价： 2980.0 元 规格： 100ul
产品信息
- 产品编号
- bs-5035R-Cy7
- 英文名称
- Anti-Apolipoprotein A V/Cy7
- 中文名称
- Cy7标记的载脂蛋白A5抗体
- 别 名
- APOA5; Apolipoprotein A V; Apo-AV; ApoA-V; Apoa5; APOA5_HUMAN; ApoAV; Apolipoprotein A-V; Apolipoprotein A5; RAP3; Regeneration associated protein 3; Regeneration-associated protein 3.
- 规格价格
- 100ul/2980元购买 大包装/询价
- 说 明 书
- 100ul
- 研究领域
- 肿瘤 细胞生物 免疫学 转录调节因子
- 抗体来源
- Rabbit
- 克隆类型
- Polyclonal
- 交叉反应
- Human, Mouse, Rat, Dog, Horse, Rabbit,
- 产品应用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
- 分 子 量
- 39kDa
- 性 状
- Lyophilized or Liquid
- 浓 度
- 1mg/ml
- 免 疫 原
- KLH conjugated synthetic peptide derived from human APOA5
- 亚 型
- IgG
- 纯化方法
- affinity purified by Protein A
- 储 存 液
- 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
- 保存条件
- Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
- 产品介绍
- background:
The protein encoded by this gene is an apolipoprotein that plays an important role in regulating the plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. Mutations in this gene have been associated with hypertriglyceridemia and hyperlipoproteinemia type 5. This gene is located proximal to the apolipoprotein gene cluster on chromosome 11q23. Alternatively spliced transcript variants encoding the same protein have been identified. [provided by RefSeq, Oct 2009].
Function:
Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages.
Subunit:
Interacts with GPIHBP1.
Subcellular Location:
Secreted.
Tissue Specificity:
Liver and plasma.
Post-translational modifications:
Phosphorylation sites are present in the extracellular medium.
DISEASE:
Defects in APOA5 are a cause of hyperlipoproteinemia type 5 (HLPP5) [MIM:144650]. HLPP5 is characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A) [MIM:232200].
Similarity:
Belongs to the apolipoprotein A1/A4/E family.
Database links:Entrez Gene: 116519Human
Omim: 606368Human
SwissProt: Q6Q788Human
Unigene: 283923Human
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.